GlassScriptPhysician profile
Ashley Garrett Biven
NPI 1598501389
$1,667.37
in general payments reported to CMS, 2019-2025
24 companies · $1,616 in 2025
The $1,616 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $51.50 · 2025: $1,616.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,667.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,667.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $253.30 | 2024-2025 | Caplyta |
| Pfizer INC. | $183.02 | 2025 | |
| Abbvie INC. | $182.25 | 2025 | |
| Novo Nordisk INC | $170.50 | 2025 | Wegovy, Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $147.60 | 2024-2025 | |
| Lilly USA, LLC | $119.71 | 2025 | Mounjaro, Kisunla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $90.97 | 2024-2025 | Jardiance |
| Glaxosmithkline, LLC. | $58.47 | 2025 | Trelegy Ellipta, Arexvy |
| Corcept Therapeutics | $56.92 | 2025 | Korlym |
| Phathom Pharmaceuticals, INC. | $53.25 | 2025 | Voquezna |
| Merck Sharp & Dohme LLC | $50.21 | 2025 | Verquvo |
| Exact Sciences Corporation | $31.99 | 2025 | Cologuard Collection Kit |
| Insulet Corporation | $31.20 | 2025 | Omnipod |
| Dexcom, INC. | $29.61 | 2025 | Dexcom G6 Transmitter |
| Sumitomo Pharma America, INC. | $27.87 | 2025 | Gemtesa |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cipher Pharmaceuticals US LLC | $26.73 | 2025 | Spinosad, Natroba |
| Dynavax Technologies Corporation | $25.66 | 2025 | Heplisav-B |
| Biogen, INC. | $25.43 | 2025 | Zurzuvae |
| Vanda Pharmaceuticals INC. | $22.61 | 2025 | Fanapt |
| Axsome Therapeutics, INC. | $17.41 | 2025 | Auvelity |
| Astellas Pharma US INC | $17.28 | 2025 | Veozah |
| Esperion Therapeutics, INC. | $15.64 | 2025 | Nexletol |
| Amgen INC. | $15.30 | 2025 | Repatha, Otezla |
| Ironwood Pharmaceuticals, INC | $14.44 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Biven listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.